Psychedelic therapy has emerged as a potential treatment approach for individuals with obsessive-compulsive disorder (OCD). Psychedelics such as psilocybin, LSD, and ayahuasca are being studied for their therapeutic effects on various mental health conditions, including OCD. Psychedelic therapy involves the administration of a moderate to high dose of a psychedelic substance in a controlled and supportive therapeutic setting, accompanied by preparatory and integration sessions.

Preliminary research suggests that psychedelic therapy may offer unique benefits for individuals with OCD. The altered state of consciousness induced by psychedelics can lead to a temporary dissolution of the rigid patterns of thought and behavior characteristic of OCD. This can provide individuals with a different perspective on their obsessive thoughts and compulsive behaviors, potentially leading to a reduction in symptoms and an increased sense of psychological flexibility.

Psychedelic therapy for OCD often involves a combination of the pharmacological effects of the psychedelic substance and the therapeutic support provided by trained professionals. The therapy session is typically guided by therapists who help individuals navigate their psychedelic experience and provide emotional support and guidance. Integration sessions following the psychedelic session are crucial for individuals to make sense of their experiences and apply insights gained during the session to their daily lives.

It's important to note that psychedelic therapy for OCD is still in the early stages of research, and more studies are needed to establish its safety, efficacy, and optimal protocols. The therapy should only be conducted under the supervision of trained professionals in a controlled environment. Additionally, psychedelic therapy is not a standalone treatment but should be integrated into a comprehensive treatment plan that may include other therapeutic modalities and support systems.

Despite the ongoing research, early findings suggest that psychedelic therapy holds promise for individuals with OCD. Studies have reported positive outcomes, including a reduction in OCD symptoms, improved quality of life, and increased psychological well-being. However, it's crucial to approach psychedelic therapy with caution and ensure that it is undertaken within a legal and ethical framework, with appropriate safeguards in place.

Eating disorder treatment involves a comprehensive approach to address the physical, psychological, and emotional aspects of these complex disorders. The primary goals of treatment are to restore a healthy relationship with food, address underlying psychological factors, and promote overall well-being. Treatment plans are typically individualized based on the specific eating disorder diagnosis, severity, and the needs of the individual.

The first step in eating disorder treatment is often a thorough assessment conducted by healthcare professionals specializing in eating disorders, such as psychiatrists, psychologists, and registered dietitians. This assessment helps in determining the appropriate level of care and developing a personalized treatment plan. Treatment options may include outpatient therapy, intensive outpatient programs (IOP), partial hospitalization programs (PHP), or inpatient hospitalization for more severe cases.

Psychotherapy, particularly cognitive-behavioral therapy (CBT), is a cornerstone of eating disorder treatment. CBT helps individuals identify and challenge dysfunctional thoughts and behaviors related to food, body image, and self-esteem. It also focuses on developing healthy coping mechanisms and enhancing self-compassion. Other types of therapy, such as dialectical behavior therapy (DBT) and interpersonal therapy (IPT), may also be utilized depending on the specific needs of the individual.

Nutritional counseling is a crucial component of eating disorder treatment. Registered dietitians work with individuals to develop balanced and flexible meal plans, normalize eating patterns, and address any nutritional deficiencies or imbalances. They also provide education on intuitive eating, portion control, and mindful eating practices. Nutritional counseling helps individuals establish a healthy relationship with food and promotes long-term recovery.

In some cases, medication may be prescribed as part of the treatment plan. Medications such as selective serotonin reuptake inhibitors (SSRIs) or other antidepressants may be used to address co-occurring conditions, such as depression or anxiety. Medication can support the overall treatment process by reducing symptoms, stabilizing mood, and addressing any underlying mental health concerns.

A migraine stage chart is a visual representation that illustrates the different stages of a migraine attack. Migraines typically progress through four distinct stages: prodrome, aura, headache, and postdrome. The chart provides a helpful tool for individuals to track and better understand the course of their migraines, as well as to communicate their experiences with healthcare professionals.

The prodrome stage is the initial phase of a migraine attack and can occur hours or even days before the headache phase. Common prodrome symptoms include fatigue, mood changes, food cravings, neck stiffness, and increased sensitivity to light and sound. The chart may include a section dedicated to recording these early warning signs, allowing individuals to anticipate and prepare for an impending migraine.

The aura stage is characterized by neurological symptoms that often precede or accompany the headache phase of a migraine. Visual disturbances, such as flashes of light or blind spots, are the most common aura symptoms, but other sensory, motor, or cognitive disturbances may also occur. The chart may include an area to document the type and duration of aura symptoms, enabling individuals to recognize patterns and discuss them with their healthcare providers.

The headache stage is the most debilitating phase of a migraine attack. It is typically characterized by severe, throbbing head pain, often accompanied by nausea, vomiting, and sensitivity to light and sound. The chart may provide space to rate the intensity and duration of the headache, as well as to record any associated symptoms or triggers. This information can help individuals and healthcare professionals assess the effectiveness of treatment interventions.

The postdrome stage, also known as the migraine hangover, occurs after the headache phase subsides. During this stage, individuals may experience fatigue, difficulty concentrating, and a general feeling of exhaustion. The chart may include a section to track the duration and severity of postdrome symptoms, as well as any strategies used to manage or alleviate them. This data can assist individuals in recognizing their post-migraine patterns and adjusting their activities accordingly.

Eating disorders are serious mental health conditions characterized by disordered eating behaviors and distorted body image. The three most common types of eating disorders are anorexia nervosa, bulimia nervosa, and binge-eating disorder. People with anorexia nervosa often restrict their food intake, leading to significant weight loss and an intense fear of gaining weight. Bulimia nervosa involves cycles of binge eating followed by compensatory behaviors such as self-induced vomiting or excessive exercise. Binge-eating disorder is characterized by recurrent episodes of uncontrollable overeating without compensatory behaviors.

Eating disorders can have severe physical, psychological, and social consequences. Physical health complications may include malnutrition, electrolyte imbalances, gastrointestinal problems, and hormonal disturbances. Psychological effects can range from low self-esteem and depression to anxiety disorders and obsessive-compulsive behaviors. Socially, individuals with eating disorders may experience isolation, strained relationships, and difficulties in daily functioning.

The causes of eating disorders are complex and multifactorial, involving a combination of genetic, environmental, and psychological factors. Biological factors, such as imbalances in brain chemicals or hormonal abnormalities, may contribute to the development of eating disorders. Environmental influences, such as societal pressures for thinness and cultural norms, can also play a significant role. Additionally, psychological factors like perfectionism, low self-esteem, and body dissatisfaction contribute to the risk of developing an eating disorder.

Early detection and intervention are crucial in the treatment of eating disorders. Seeking professional help from healthcare providers experienced in the treatment of eating disorders is essential. Treatment approaches typically involve a multidisciplinary team, including therapists, dietitians, and medical professionals. The primary goals of treatment are to restore physical health, address underlying psychological issues, normalize eating behaviors, and promote long-term recovery.

Recovery from an eating disorder is possible with appropriate treatment and support. Treatment plans are tailored to the individual's specific needs and may include psychotherapy, nutritional counseling, support groups, and, in some cases, medication. Therapy, such as cognitive-behavioral therapy (CBT), helps individuals develop healthier attitudes towards food and body image, challenge distorted thinking patterns, and develop coping strategies. Nutritional counseling focuses on establishing a balanced relationship with food and promoting a healthy approach to eating. Support from loved ones, as well as ongoing aftercare and relapse prevention strategies, are crucial for sustained recovery.

Depression treatment encompasses a range of interventions and approaches aimed at alleviating symptoms, improving functioning, and promoting overall well-being in individuals with depression. Treatment options can include psychotherapy, medication, lifestyle changes, and other complementary therapies. The choice of treatment depends on the severity of depression, individual preferences, and the guidance of healthcare professionals.

Psychotherapy, also known as talk therapy or counseling, is a common and effective treatment for depression. Different types of psychotherapy, such as cognitive-behavioral therapy (CBT), interpersonal therapy (IPT), and psychodynamic therapy, can be employed. These therapies help individuals identify and change negative thought patterns, develop healthier coping mechanisms, improve interpersonal relationships, and address underlying emotional issues contributing to depression.

Medication, such as selective serotonin reuptake inhibitors (SSRIs) or other antidepressants, may be prescribed for moderate to severe depression. These medications work to rebalance brain chemistry and alleviate depressive symptoms. It's important to note that medication should be prescribed and monitored by a qualified healthcare professional, as they can have potential side effects and require careful management.

Lifestyle changes can play a significant role in depression treatment. Engaging in regular physical exercise has been shown to have mood-boosting effects and can reduce depressive symptoms. Adequate sleep, a balanced diet, and stress reduction techniques, such as mindfulness or relaxation exercises, can also contribute to overall well-being and help manage depression. Additionally, social support and maintaining a supportive network of family and friends can provide emotional comfort and assistance during treatment.

Complementary therapies, such as yoga, meditation, art therapy, or acupuncture, may be used in conjunction with traditional approaches to depression treatment. While evidence varies for these therapies, they can offer additional tools to manage depression symptoms and promote self-care. It's important to consult with healthcare professionals and ensure the integration of complementary therapies into a comprehensive treatment plan.

Psychedelic therapy: what is it?

It is a psychiatric method that uses psychedelic substances to treat various mental disorders. Our first thoughts might bring to mind drugs like LSD, which were fashionable in the 1950s and 1960s and were eventually banned.

However, science has been conducting regulated and medically recognized studies for decades. For example, there is evidence that psilocybin is an alkaloid with great mental health potential. It is the active ingredient of “magic mushrooms”, which are tropical mushrooms that could serve as antidepressants.

Research from the University of Maryland, Baltimore, highlights how psychedelic treatments could change the way we approach many disorders. We must remember that traditional approaches to severe depression or post-traumatic stress disorder are not always effective. Safe administration of psychedelic substances could be beneficial in this case.

In what areas has psychedelic therapy proven to be beneficial?

Thanks to studies by medical, academic and pharmacological institutions, the benefits of these substances are becoming increasingly known. Microdosing causes changes in the mechanisms of the brain that result in calming of emotional pain, increased mental focus, and altered perception. Significant improvements were achieved in the following areas:

Dependency

Persistent depression and anxiety

Terminal cancer with existential fears. In this case, the treatment improves the mood of patients.

Research published in The Lancet shows that treatment with methylenedioxymethamphetamine reduces symptoms of post-traumatic stress disorder in soldiers, police officers and firefighters, for example.

EPIsoDE - A Phase II Clinical Trial to Investigate the Efficacy and Safety of Psilocybin in Treatment-Refractory Unipolar Depression

Depression is one of the most common illnesses of all. Resistance to therapy is also common. In the approval and effectiveness studies of the various medications, a third to half of the patients do not respond to treatment lasting several weeks. Despite intensive research, there is still a lack of effective therapeutic approaches in the event that the previously approved medications do not work.

A possible approach in the treatment of therapy-resistant depression is the use of psilocybin. Psilocybin is a naturally occurring substance from special types of mushrooms. In humans, psilocybin has a psychoactive effect and can produce euphoria, physical lightness and hallucinations. In addition to findings from the 1950s and 60s, more recent Clinical Trials Using Psilocybine suggest the effectiveness and safety of psilocybin in the treatment of treatment-resistant depression, depression and anxiety associated with terminal illnesses, obsessive-compulsive disorder and substance use disorders. The aim of the project is a bicentric clinical study with patients with treatment-resistant depression. The aim of this study is to demonstrate the safety of the application and to obtain initial indications of the effectiveness of the therapy.

As is the case with psilocybin in the treatment of depression, there is no immediate commercial interest from pharmaceutical companies in further clinical development for many new, potentially effective therapeutic approaches due to a limited range of applications or high scientific and technical risks. One of the central challenges is to investigate such therapeutic approaches so that patients can benefit from them as quickly as possible. In the “Early Clinical Studies” funding measure, the BMBF therefore promotes the implementation of science-initiated early clinical studies up to Phase II and helps ensure that new therapeutic approaches are pursued further.

Psychotherapeutic depression treatment

At best, depression should be treated with psychotherapy and, in more severe cases, with medication. Various psychotherapeutic therapy methods are suitable for treating depression. Cognitive behavioral therapy has proven to be particularly effective in bringing about a rapid reduction in symptoms. This is a therapeutic procedure that specifically addresses the patient's symptoms and addresses the patient's individual problems so that personal suffering is reduced and an active everyday life is possible again. To this end, various steps are taken in structured therapy sessions to treat the clinical picture of depression. The patient should increase their activity, work on their social contacts, learn to give up false beliefs about themselves and learn problem-solving strategies for everyday life and for future crises. During therapy, problems are analyzed, exercises are carried out, homework is assigned and discussed.

Pharmacological depression treatment

Depression is treated medically with so-called antidepressants. In Germany there are around 30 approved active ingredients2 that are used for this purpose. Most antidepressants do not work immediately, but usually take effect after three to six weeks. The drugs aim to increase the concentration of the important messenger substances (neurotransmitters) norepinephrine and serotonin in the brain. However, their mode of action and their side effects differ greatly. An exception is the newly approved esketamine nasal spray, which has a significantly faster effect via NMDA receptors in the brain. Depending on the situation, other illnesses and medications taken, a specific antidepressant is selected for the patient in consultation with psychiatric professionals.

Treatment-resistant depression – When treatment doesn’t work

If there is no improvement in depressive symptoms as a result of psychotherapeutic and drug treatments, it is referred to as therapy-resistant depression. Depending on the definition, treatment-resistant depression can also exist if two attempts at drug treatment have failed.3 In some cases, it may happen that the therapy was not carried out correctly and therefore did not work. In such cases one speaks of “pseudotherapy resistance”.

“The world urgently needs a new way to treat mental health issues, and at PsyRx we believe psychedelics are a big part of the solution,” says Itay Hecht.

Hecht is CEO and co-founder of this Israeli company, which is developing standardized pharmaceutical grade psychedelics from natural sources — not synthetics — as active pharmaceutical ingredients.

Using an agro-medical bioreactor invented at the Hebrew University Faculty of Agriculture, PsyRx produces psychedelic botanic extracts psilocybin (from “magic” mushrooms) and ibogaine (from the root bark of the iboga shrub).

Psilocybin has been shown to have positive effects in treating depression, anxiety and addiction, and has been suggested as a potential treatment for obesity, PTSD, cluster headaches and more.

Ibogaine has shown promise as an anti-addiction drug, among other indications. PsyRx is focusing on its potential to improve current SSRI (selective serotonin reuptake inhibitor) antidepressants.

“SSRIs have some very bad side effects on libido and appetite, and patients often stop using them. We believe adding a microdose of ibogaine will counter those effects and make a better drug,” Hecht says, emphasizing that microdoses of psychedelic substances do not cause hallucinations.

“We are starting small animal trials soon to check safety and efficacy. Hopefully, in a year’s time, we can start human trials” to test this ibogaine application, he tells ISRAEL21c.

ON-TREND

Adding psychedelics to mainstream drugs may seem a bit “out there,” but in fact it’s on-trend.

According to market intelligence report CB Insights, funding for psychedelic medicine companies is growing rapidly as traditional pharma giants see declines in return on investment for drug R&D and are interested in exploring alternative products. Consumer interest in hallucinogenic drugs also is growing, according to this report.

They couldn't stop him. An 18-year-old consumed psilocybin mushrooms, also known as magic mushrooms, with friends. Two people also took mushrooms, and another person limited himself to smoking weed. During the session, the 18-year-old initially isolated himself from the others in the bathroom. Suddenly he came out naked, behaved unusually aggressively and showed a strong urge to jump from the balcony.

The other two people, who were also on a mushroom trip, were too busy with themselves to intervene. The person, who was just stoned, tried to stop him, but couldn't prevent the accident. The 18-year-old did not survive the fall from the second floor.

Fatal accidents following psilocybin are rare, but do occur

How could that happen? Examinations of the stomach contents as well as further blood and urine analyzes led to the conclusion that he was actually only under the influence of psilocybin. The cannabis active ingredient THC could only be detected in low concentrations. This suggests that the last joint was some time ago and did not play a role at the time of the accident.

The 18-year-old grew the mushrooms himself in his apartment. His friends said he had consumed the mushrooms in the past to overcome his shyness. But that is certainly not enough to explain his behavior. There were no other signs of psychological problems.

The medical team reporting on the case has researched other cases. According to the research, fatal accidents appear to be rare, but they do occur from time to time. According to the authors, the case of the 18-year-old demonstrates that a trip can be associated with incalculable risks even under seemingly safe conditions, such as consumption with friends.

Low toxicity, but exceptional psychological situation

The immediate toxicity of psilocybin, however, is rather low. Based on animal experiments with rats, it can be estimated that an adult human would have to eat around 17 kilograms of fresh psilocybin mushrooms to absorb a potentially fatal dose. Since the body usually reacts with nausea and vomiting at this amount, it is not to be expected that users will die from the immediate effect. Above all, it is unexpected behavior that can lead to life-threatening accidents when intoxicated.

However, the dose can play a role. The higher the amount of psilocybin consumed, the higher the likelihood of particularly intense intoxication. Intoxication can cause exceptional psychological situations, particularly in inexperienced people, but also in experienced people. This is shown by a survey among consumers in which almost 2,000 people took part.

Horror trip even for experienced consumers

Study leader Roland Griffiths and his team from Johns Hopkins University in the USA asked those surveyed to remember their worst mushroom horror trip and to provide information about it. As was to be expected, the majority of participants took part who had had multiple experiences with hallucinogenic mushrooms. Her worst horror trip was preceded by between six and ten episodes of mushroom consumption. At the time of the survey they were on average 30 years old.

Around three quarters of those surveyed said that they were actually in good spirits before their horror trip. Most of them consumed with friends and felt that they were in good hands. However, only three percent of those surveyed had a “tripsitter” on their side. This is a person who stays sober and can help if the worst comes to the worst.